Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The effect of micronised fenofibrate on paraoxonase activity in patients with coronary heart disease.

Diabetes & metabolism - 1 Dec 2003

Paragh G, Seres I, Harangi M, Balogh Z, Illyés L, Boda J, Szilvássy Z, Kovács P

Abstract excerpt

OBJECTIVE: To evaluate the effect of micronised fenofibrate on serum paraoxonase (PON) and lipoprotein levels in coronary heart disease patients with type IIb hyperlipidemia. PATIENTS AND METHODS: Fifty-two patients were investigated for the three-month effect of 200 mg per day micronised fenofibrate on the serum enzyme activity and concentration of PON and their relationship with serum lipids, high-density...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Apolipoprotein A-I
Share to Apolipoproteins B

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Aryldialkylphosphatase

Share to Cholesterol, HDL

Share to Cholesterol, LDL

Share to Coronary Disease

Share to Hyperlipoproteinemia Type II

Share to Hypolipidemic Agents

Source

Identifiers

PMID: 14707891
DOI: 10.1016/s1262-3636(07)70077-0

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The effect of micronised fenofibrate on paraoxonase activity in patients with coronary heart disease.PMID 14707891Read ↗

Overview of fenofibrate.Semantic proximity Read ↗

Effect of fenofibrate therapy on paraoxonase1 status in patients with low HDL-C levels.Semantic proximity Read ↗

Pharmacological Interactions of Paraoxonase 1 (PON1): A HDL-Bound Antiatherogenic Enzyme.Semantic proximity Read ↗

Effects of fenofibrate on plasma oxidized LDL and 8-isoprostane in a sub-cohort of GOLDN participants.Semantic proximity Read ↗

Ciprofibrate treatment in patients with atherogenic lipoprotein phenotype: effects on HDL quality, LDL susceptibility to oxidation and DNA damage.Semantic proximity Read ↗

[Can cardiovascular events be prevented by raising HDL cholesterol?].Semantic proximity Read ↗

Effects of niceritrol on levels of serum lipids, lipoprotein(a), and fibrinogen in patients with primary hypercholesterolemia.Semantic proximity Read ↗

Serum paraoxonase after myocardial infarction.Semantic proximity Read ↗

Ciprofibrate treatment decreases non-high density lipoprotein cholesterol and triglycerides and increases high density lipoprotein cholesterol in patients with Frederickson type IV dyslipidemia phenotype.Semantic proximity Read ↗

Impact of bezafibrate and atorvastatin on lipoprotein subclass in patients with type III hyperlipoproteinemia: result from a crossover study.Semantic proximity Read ↗

Effect of fenofibrate therapy and ABCA1 polymorphisms on high-density lipoprotein subclasses in the Genetics of Lipid Lowering Drugs and Diet Network.Semantic proximity Read ↗

Action of ciprofibrate in type IIb hyperlipoproteinemia: modulation of the atherogenic lipoprotein phenotype and stimulation of high-density lipoprotein-mediated cellular cholesterol efflux.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.